Other antibodies used to target liposomes include: anti-CD22 antibody targeting Non-Hodgkin’s Lymphoma [170]; anti-CD19 antibody targeting malignant B cells [171]; anti-CD44 antibody targeting cancer stem cells [45,172]; and anti-MT1-MMP (membrane type 1 matrix metalloproteinase) targeting tumour and neovascularity [173]. This evidence concerns the gene MMP14 and non-Hodgkin lymphoma.